by Madaline Spencer | Nov 21, 2025
The U.S. Food and Drug Administration (FDA) has approved Redemplo (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome (FCS). FCS is an inherited condition that disrupts the normal breakdown of fats in the body, causing large amounts...
by Madaline Spencer | Nov 20, 2025
The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible NPM1 mutation. Acute myeloid leukemia (AML) is a cancer that affects the blood and bone...
by Madaline Spencer | Nov 18, 2025
Aman Chauhan, MD, Oncologist at the University of Miami, discusses details of a phase 3 study testing paltusotine in patients with carcinoid syndrome due to neuroendocrine tumors (NETs). NETs are rare tumors that usually develop in the GI tract or lungs,...
by Madaline Spencer | Nov 17, 2025
Alexandra C. Bayer Wildberger, PhD, Post-Doctoral Associate at Yale School of Medicine, discusses the shift to precision medicine in myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal...
by Madaline Spencer | Nov 14, 2025
Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA is a type of vasculitis causing...
